ABBOTT PARK, Ill., Sept. 17, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received CE Marking (Conformite Europeenne) in Europe for the FreeStyle Optium Neo Blood Glucose and ...

Abbott’s continuous glucose monitoring (CGM) device, the FreeStyle Libre, has been integrated with Glooko’s digital platform for diabetes management. The integration is available for ...

Diabetes care at Abbott Laboratories has returned to sales growth as ex-U.S. sales of its new FreeStyle Libre kick in and the impact of diabetes device reimbursement reductions dropped off the books.

Abbott Laboratories won a CE mark for its FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System, expanding its presence on the European diabetes market with a next-gen device.

The added compatibility with Abbott’s FreeStyle Libre 2 Plus will open Insulet’s pump to more of the US diabetes market, estimated to be worth $9.6bn in 2023. By 2033, ...

A small number of sensors that read blood sugar levels continuously may give incorrect info. Here's how to check your FreeStyle Libre 3 for a replacement.

Abbott (NYSE: ABT) announced today it has received CE Marking (Conformite Europeenne) in Europe for the FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System ™.The new icon-driven ...

Abbott’s continuous glucose monitoring (CGM) device, the FreeStyle Libre, has been integrated with Glooko’s digital platform for diabetes management. The integration is available for ...

In an email response to CNET, a spokesperson for Abbott said the company estimates it may impact less than 1% of FreeStyle Libre 3 users in the US, but the company is encouraging all customers to ...